Cargando…
SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
Prior models have been developed to predict survival for patients with esophagogastric cancer undergoing curative treatment or first‐line chemotherapy (SOURCE models). Comprehensive clinical prediction models for patients with esophagogastric cancer who will receive second‐line chemotherapy or best...
Autores principales: | Kuijper, Steven C., Pape, Marieke, Haj Mohammad, Nadia, van Voorthuizen, Theo, Verhoeven, Rob H. A., van Laarhoven, Hanneke W. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107625/ https://www.ncbi.nlm.nih.gov/pubmed/36451334 http://dx.doi.org/10.1002/ijc.34385 |
Ejemplares similares
-
Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019) -
Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
por: Pape, Marieke, et al.
Publicado: (2023) -
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022) -
A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands
por: Pape, Marieke, et al.
Publicado: (2023) -
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)